Cargando…
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic
EC1456 is a folate-tubulysin conjugate constructed with an all-D enantiomeric spacer/linker configuration. When tested against folate receptor (FR)-positive cells, EC1456 demonstrated dose-responsive activity with an approximate 1000-fold level of specificity. Treatment of nude mice bearing FR-posit...
Autores principales: | Reddy, Joseph A., Dorton, Ryan, Bloomfield, Alicia, Nelson, Melissa, Dircksen, Christina, Vetzel, Marilynn, Kleindl, Paul, Santhapuram, Hari, Vlahov, Iontcho R., Leamon, Christopher P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997627/ https://www.ncbi.nlm.nih.gov/pubmed/29895863 http://dx.doi.org/10.1038/s41598-018-27320-5 |
Ejemplares similares
-
Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent
por: Reddy, Joseph A., et al.
Publicado: (2020) -
Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma
por: Szigetvari, Nicholas M., et al.
Publicado: (2018) -
Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causes
por: Lu, Yingjuan J., et al.
Publicado: (2021) -
Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate
por: Lu, Yingjuan, et al.
Publicado: (2011) -
Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies
por: Lu, Yingjuan J., et al.
Publicado: (2019)